Did Lenivia Approvals Mark a New Chapter for Zoetis' (ZTS) Innovation Narrative?

• Zoetis Inc. recently announced that Health Canada approved Lenivia, a new monoclonal antibody therapy for canine osteoarthritis pain, and received a positive opinion from the European Medicines Agency's CVMP, paving the way for potential EU approval and commercial rollout in 2026.
• This regulatory progress highlights Zoetis's ability to expand its innovative product portfolio and address significant unmet needs in the fast-growing companion animal market.
• We'll explore how Lenivia's approval and European progress could reshape Zoetis's investment narrative as innovation becomes even more essential.

We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Zoetis Investment Narrative Recap

To be a Zoetis shareholder, you need to believe in the company's ability to drive consistent growth through innovative therapies for unmet animal health needs, especially in pain management for companion animals. The recent regulatory advances for Lenivia signal ongoing R&D momentum but may not immediately resolve the most important short-term challenge: slower-than-expected OA pain product adoption in key markets stemming from safety concerns and shifting sentiment, which remains a meaningful risk to watch.

One particularly relevant update is the rollout of the new, longer-acting Lenivia therapy, which comes on the heels of the updated Librela label in the US earlier this year. Both announcements are pivotal for Zoetis's pain franchise, as they directly address medical needs for chronic canine osteoarthritis, reinforcing the importance of innovation as a growth catalyst for the business.

Yet, despite these advancements, growing social media-driven hesitancy and concerns about product safety are still key factors that investors should be aware of...

Read the full narrative on Zoetis (it's free!)

Zoetis' narrative projects $10.9 billion revenue and $3.2 billion earnings by 2028. This requires 5.2% yearly revenue growth and a $0.6 billion earnings increase from $2.6 billion.

Uncover how Zoetis' forecasts yield a $188.83 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members put Zoetis's fair value between US$153 and US$188.83, with eight distinct viewpoints represented. With innovation in osteoarthritis therapies showing progress, opinions vary widely on the company's future growth and risk profile, see how your own view compares.

Explore 8 other fair value estimates on Zoetis - why the stock might be worth as much as 28% more than the current price!

Build Your Own Zoetis Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Zoetis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com